Urinary MCP-1 and RBP: Independent predictors of renal outcome in macroalbuminuric diabetic nephropathy

Titan, Silvia Maria de Oliveira; Vieira, J.M.; Dominguez, Wagner Vasques; Moreira, Sonia; Pereira, Aparecido B.; Barros, Rui Toledo; Zatz, Roberto

doi:10.1016/j.jdiacomp.2012.06.006

Cited by 103 publications

(79 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We chose to study two inflammatory biomarkers: monocyte chemotactic protein-1 (MCP-1) and IL-18. MCP-1 has been associated with DKD progression in two small studies (8,9), and IL-18 is associated with eGFR decline in nondiabetic populations (10). We also studied kidney injury molecule-1 (KIM-1), which has been associated with incident and progressive CKD in the Multi-Ethnic Study of Atherosclerosis (MESA) Study cohort (11), and a repair/fibrosis marker, YKL-40, which is upregulated in AKI and elevated in CKD and DKD (12,13).…”

Section: Introductionmentioning

confidence: 99%

Association of Urinary Biomarkers of Inflammation, Injury, and Fibrosis with Renal Function Decline: The ACCORD Trial

Nadkarni

Rao

Ismail‐Beigi

et al. 2016

CJASN

View full text Add to dashboard Cite

Background and objectives Current measures for predicting renal functional decline in patients with type 2 diabetes with preserved renal function are unsatisfactory, and multiple markers assessing various biologic axes may improve prediction. We examined the association of four biomarker-to-creatinine ratio levels (monocyte chemotactic protein-1, IL-18, kidney injury molecule-1, and YKL-40) with renal outcome.Design, setting, participants, & measurements We used a nested case-control design in the Action to Control Cardiovascular Disease Trial by matching 190 participants with $40% sustained eGFR decline over the 5-year follow-up period to 190 participants with #10% eGFR decline in a 1:1 fashion on key characteristics (age within 5 years, sex, race, baseline albumin-to-creatinine ratio within 20 mg/mg, and baseline eGFR within 10 ml/min per 1.73 m 2 ), with #10% decline. We used a Mesoscale Multiplex Platform and measured biomarkers in baseline and 24-month specimens, and we examined biomarker associations with outcome using conditional logistic regression.Results Baseline and 24-month levels of monocyte chemotactic protein-1-to-creatinine ratio levels were higher for cases versus controls. The highest quartile of baseline monocyte chemotactic protein-1-to-creatinine ratio had fivefold greater odds, and each log increment had 2.27-fold higher odds for outcome (odds ratio, 5.27; 95% confidence interval, 2.19 to 12.71 and odds ratio, 2.27; 95% confidence interval, 1.44 to 3.58, respectively). IL-18-tocreatinine ratio, kidney injury molecule-1-to-creatinine ratio, and YKL-40-to-creatinine ratio were not consistently associated with outcome. C statistic for traditional predictors of eGFR decline was 0.70, which improved significantly to 0.74 with monocyte chemotactic protein-1-to-creatinine ratio.Conclusions Urinary monocyte chemotactic protein-1-to-creatinine ratio concentrations were strongly associated with sustained renal decline in patients with type 2 diabetes with preserved renal function.

show abstract

Section: Introductionmentioning

confidence: 99%

Association of Urinary Biomarkers of Inflammation, Injury, and Fibrosis with Renal Function Decline: The ACCORD Trial

Nadkarni

Rao

Ismail‐Beigi

et al. 2016

CJASN

View full text Add to dashboard Cite

show abstract

“…A recent study showed that urinary MCP-1 was significantly higher in patients with doubling of serum creatinine or death, in the Cox regression, urinary MCP-1 excretion was positively associated with the risk of serum creatinine doubling or death, and urinary MCP-1 remained as significant independent predictor of this primary outcome (doubling of serum creatinine or death) (Titan et al 2012). All the data mentioned above indicated that urinary MCP-1 could be a prognostic biomarker for progression of DN, further investigations need to be performed to confirm whether urinary MCP-1 has a role in the setting of normoalbuminuria and microalbuminuria in DN (Wang et al 2013).…”

Section: 2monocyte Chemoattractant Protein-1 (Mcp-1)mentioning

confidence: 89%

Novel Biomarkers for Early Diagnosis and Progression of Diabetic Nephropathy

2015

ARC Journal of Diabetes and Endocrinology

View full text Add to dashboard Cite

show abstract

“…10 However, when studied prospectively, the prognostic ability of urinary TGF-β has been mixed; one study predicted independently the progression of diabetic nephropathy after a 2-year follow-up 11 whereas another did not. 12 Connective tissue growth factor (CTGF) is induced by various pathways that include TGF-β, angiotensin II, signaling mothers against decapentaplegic peptide (Smad), and hypoxia inducible factor. 13 A relatively large cross-sectional study in type 1 DM patients found that urinary CTGF levels in those with diabetic nephropathy were significantly higher than in patients with microalbuminuria or normoalbuminuria.…”

Section: Extracellular Matrix Markersmentioning

confidence: 99%

“…45 In a recent prospective study that followed type 2 DM patients for an average of 30 months, urinary retinol-binding protein appeared to be an independent predictor of disease progression (risk of dialysis, doubling of serum creatinine or death) after adjusting for confounding factors such as creatinine clearance, proteinuria, and blood pressure. 12 Monocyte chemoattractant protein-1 is a secreted chemokine that is thought to play an important role in the pathogenesis of tubulointerstitial disease by activating macrophage recruitment in diabetic nephropathy. 46 Subsequently, urinary monocyte chemoattractant protein-1 levels have been found to be significantly elevated in patients with diabetic nephropathy and advanced tubulointerstitial lesions.…”

Section: Markers Of Tubulointerstitial Damagementioning

confidence: 99%

Urinary biomarkers of diabetic nephropathy

Mehta¹,

Cabrera²,

Upputalla³

et al. 2013

CBF

View full text Add to dashboard Cite

Abstract:The fervent search for an early biomarker for diabetic nephropathy is continuing because this entity has become the leading cause of end-stage renal disease in many countries. Novel biomarkers are being described in a high-speed manner. Using urine as a biological source is especially appealing given its ease of collection and its ability to serve as a direct conduit to the site of injury. We begin by briefly discussing the merits and pitfalls of our gold standard of microalbuminuria, and shift quickly to several promising nontraditional protein and messenger (m)RNA biomarkers. The quality of the evidence for using urinary podocyte as a marker will be described. Exploring entire sets of protein in humans in terms of proteomics has been a favorite approach in the last decade because the technology of protein separation and mass spectrometry allows for the unbiased search for new biomarkers. Isolating urinary microRNA may become yet another preferred method because these small, noncoding mRNA that regulate gene expression are particularly stable and apt for biomarker studies. Finally, the latest development is perhaps the study of exosomes, which are nanometer particles derived from the fusion of internal vesicles to the plasma membrane. These particles harbor protein, mRNA, and microRNA that may be isolated for further study. With the advent of newer technologic approaches, we hope that these newly discovered biomarkers will be rigorously tested in large, prospective, clinical trials so they can be implemented in clinical practice.

show abstract

Urinary MCP-1 and RBP: Independent predictors of renal outcome in macroalbuminuric diabetic nephropathy

Cited by 103 publications

References 59 publications

Association of Urinary Biomarkers of Inflammation, Injury, and Fibrosis with Renal Function Decline: The ACCORD Trial

Association of Urinary Biomarkers of Inflammation, Injury, and Fibrosis with Renal Function Decline: The ACCORD Trial

Novel Biomarkers for Early Diagnosis and Progression of Diabetic Nephropathy

Urinary biomarkers of diabetic nephropathy

Contact Info

Product

Resources

About